Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-HIV therapies - Isis/ImQuest

Drug Profile

Research programme: anti-HIV therapies - Isis/ImQuest

Alternative Names: Combination topical microbicide product - ImQuest Biosciences; IQP-0831; ISIS-5320; NSC 665353

Latest Information Update: 29 Mar 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer ImQuest Life Sciences; Isis Pharmaceuticals
  • Class Antivirals; Oligodeoxyribonucleotides; Thionucleotides
  • Mechanism of Action HIV envelope protein gp120 inhibitors; HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 29 Mar 2012 No development reported - Preclinical for HIV infections (prevention) in USA (Topical)
  • 06 Aug 2008 This programme is still in active preclinical development
  • 21 Apr 2006 Preclinical trials in HIV infections prevention in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top